3/6/2026Sciwind's Ecnoglutide Approved in China for Obesity

3/6/2026Lynk's Zemprocitinib Meets Phase III Endpoints in Atopic Dermatitis

3/6/2026Abbisko Doses First Patient in Trial of KRAS G12D Inhibitor ABSK141

3/6/2026China Approves Novo's Weekly Insulin–GLP-1 Combination Therapy for Ty...

3/6/2026Recent Executive Moves

3/5/2026CDE Issues Guidance on Subject Selection for Oncology Drug Bioequivale...

3/5/2026CMS Wins China Trial Approval for INHBE-Targeting Obesity siRNA Drug

3/4/2026Eli Lilly Advances New Oral Diabetes Therapy in China

3/4/2026Sanofi Licenses Sino Biopharm's Transplant Therapy in $135M Upfront De...

3/4/2026Antengene Strikes $1.1B+ CD19 T-Cell Engager Deal with UCB

3/4/2026Minwei Biotech's siRNA Therapy MWX401 Cleared for Clinical Trials in C...

3/4/2026Immunofoco Raises ~CNY 200M in Pre-IPO Round Ahead of Hong Kong Listin...

3/4/2026Leman Biotech Raises ~CNY 200M to Advance Metabolism-Enhanced CAR-T Pl...

3/4/2026CDE Issues Technical Guideline on Clinical Trials for Drugs Treating C...

3/4/2026CDE Invites Feedback on Draft Technical Guideline for Preventive mRNA ...

3/4/2026CSPC's Emicizumab Injection Receives Clinical Trial Approval in China

3/4/2026China Biotech Outlicensing Surges Past US$52 Billion in Early 2026

3/3/2026China Approves Five NMEs in February as Innovation Expands Globally

3/3/2026Prolium Launches with $50M to Advance China-Licensed T-Cell Engager in...

3/3/2026Rallybio to Merge with Candid Therapeutics in $505M-Funded Reverse Mer...

3/3/2026Clickmab Biotech Secures Seed+ Funding to Boost AI Antibody Design Pla...

3/3/2026LongBio Pharma's LP‑003 Shows Superior Efficacy Over Xolair in Phase ...

3/2/2026WuXi XDC Partners With Earendil Labs on Next-Generation ADC Platform

3/2/2026Sanofi Secures Two New China Approvals for Dupilumab

3/2/2026Innovent Registers Phase I Study for FIC Dual-Payload Bispecific ADC

3/2/2026NMPA Grants Conditional Approval to Sosimerasib for KRAS G12C-Mutant N...

3/2/2026NMPA Approves Rovalicitinib for First-Line Myelofibrosis

3/2/2026QL Biopharm Raises Over CNY 500M in Series C Led by OrbiMed

3/2/2026MediLink Advances HER3 ADC YL202 Into Two Phase III Trials in China

3/2/2026RemeGen NDA for RC288 Dual-Target ADC Accepted by NMPA

Page:10/829 Total number of articles:24863: [First][<<] [8] [9] [10] [11] [12] [>>] [End]